 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
DURECT CORP, (DRRX) Stock Rating Learn More
| Our Overall Rating on DURECT CORP, DRRX is Not Available | | DURECT Corporation develops pharmaceutical systems based on its proprietary drug delivery technology platforms. The company has various product candidates under development by itself and with third-party collaborators in the areas of pain, and other chronic diseases and disorders. Its primary product candidates in development include SABER-Bupivacaine, TRANSDUR-Sufentanil, ORADUR- Oxycodone, DURIN-Leuprolide, and CHRONOGESIC. SABER-Bupivacaine, a post-operative pain relief depot product candidate, is a sustained release injectible using DURECTs SABER delivery system to deliver bupivacaine. SABER is a controlled drug delivery technology that can be formulated for systemic or local administration of drugs through the parenteral or oral route. TRANSDUR-Sufentanil, a transdermal sufentanil product candidate in phase II clinical studies, uses the companys proprietary TRANSDUR delivery system to deliver sufentanil, an opioid medication, to provide chronic pain relief for up to seven days. ORADUR- Oxycodone, an oral opioid product in phase III clinical studies, would be used to decrease the potential for oxycodone abuse. ORADUR- Oxycodone uses the companys ORADUR technology, which is a SABER-based oral gel cap technology. DURIN-Leuprolide is a product candidate using the DURIN implant system to deliver the peptide leuprolide to treat Alzheimers disease. DURIN is a biodegradable polymeric implant drug delivery technology, which delivers drugs from several weeks to six months. The CHRONOGESIC Pain Therapy System is an osmotic implant that would deliver sufentanil for an extended duration. CHRONOGESIC would be used to treat chronic pain and is based on the DUROS System, an osmotic pump that delivers drugs for approximately a year in duration. DURECT also engages in the research and development pharmaceutical systems in various therapeutic areas, including chronic pain, central nervous system disorders, and cardiovascular disease. In addition, the company manufactures and sells osmotic pumps used for animal research, and various standard and custom biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products. DURECT has strategic partnerships with Pain Therapeutics, Inc.; Voyager Pharmaceutical Corporation; Endo Pharmaceuticals, Inc.; Endo Pharmaceuticals, Inc.; and NeuroSystec Corporation. The company was co-founded by Felix Theeuwes, James E. Brown, and Thomas A. Schreck in 1998. DURECT is headquartered in Cupertino, California. | | Our Not Available Rating on DRRX was issued on 11/21/2008 |
DURECT CORP Technical Rating
|
|
|
|
